Clarivate and CLEO diagnostics are making early detection of ovarian cancer a reality

Cleo Diagnostics, an ASX-listed Australian biotech, is developing a blood test for early ovarian cancer detection after 13-plus years of lab research; CEO Richard Allman says Cleo has patents pending/granted in the US and Australia. Chief Scientific Officer Andrew Stephens explains the urgency: if ovarian cancers "can be detected at an early stage before they have grown and spread, survival is about 90 percent," but today diagnosis requires surgery, and non-malignant masses are about 10 times more common than cancers, leading to many unnecessary or misdirected surgical referrals. Cleo used Clarivate's Cortellis Drug Discovery Intelligence to identify biomarker patterns for diagnostic accuracy and Derwent patent intelligence software for IP protection, plus Clarivate market research to shape commercial positioning. Allman is quoted: "This is a big help as we aim to grow the business from zero to a global diagnostics brand."

Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.